

血液病/恶性肿瘤患者侵袭性真菌病的诊断标准 与治疗原则(第五次修订版)

中国侵袭性真菌感染工作组

The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the fifth revision)

【Summary】 Invasive fungal disease (IFD) is a common yet highly lethal complication in patients with hematological malignancies receiving chemotherapy or stem cell transplantation, as well as immune suppressive conditions including aplastic anemia and other malignancies. According to the diagnostic criteria, patients are defined as proven, probable, possible and undefined IFD based on the evidence provided by histopathologic/cytologic, culture, radiographic and biomarker examinations. For the management of IFD, the major treatment strategies consist of prophylaxis, empirical, diagnostic-driven and target therapy. The Chinese Invasive Fungal Infection Working Group has developed the Chinese consensus for the diagnosis and treatment of invasive fungal disease based on international guidelines and local experience. Recently, the working group revises the consensus by update international guidelines and clinical studies in China.

【Key words】 Practice guideline; Hematologic disorders; Malignancy; Invasive fungal disease

(invasive fungal disease, IFD) 。 、 [(CAESAR)] , IFD 2.1% , (EORTC-IDG) (MSG) [1]、 (myelodysplasia syndrome, MDS)/ (IDSA) [2-4] (acute myeloid leukemia, AML) IFD , (ECIL) [5-6] , 2013 [8] (hematopoietic [7] stem cell transplantation, HSCT) , IFD 7.7% , IFD 19.0% ; (proven)、 (probable) (allo-HSCT) (auto-HSCT)1 IFD , 6 , allo-HSCT (empirical antifungal therapy)、 (diagnostic-driven antifungal therapy) (targeted antifungal therapy) auto-HSCT(9.2% 3.5%) ;allo-HSCT HLA 、HLA 4.3%、12.8% 13.2% [9] 。 IFD 。

流行病学

IFD , IFD IFD 51 HSCT , 36 (70.6%) , 14 (27.5%) , [9-10] 。 IFD

DOI:10.3760/cma.j.issn.0578-4426.2017.06.015

,100044, Email: huangxiaojun@

bjmu.edu.cn



表3

1.	($<0.5 \times 10^9/L$	10 d
2.			
3.	3	$(0.3 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$)
4. 90 d	T	(A、	alemtuzumab)
5.			
6.		()
CT	3	:	(),
		:	、 、 、
	1	:	();
	1	:	;MRI/CT
	2	:	1 : / ;
(、)	1.	:	1 :
()	2.	:	/
(、)			GM

:G (1,3)-β-D- ;GM

, IFD (), / GM/G IFD [20-21]

, CT(HRCT) (polymerase chain reaction,PCR), [14]

CT IFD [22] (>1 cm)

IFD 的治疗

, IFD () (primary anti-fungal prophylaxis)

, IFD IFD , IFD

, IFD $\geq 3\% \sim 5\%$ $\geq 10\%$ [23]

IFD GVHD HSCT [14-17] (IFD 15%)、 (5%) (1% ~ 2%) , / IFD HSCT

2. : IFD (G) IFD (GM) IFD [4-5, 14]

GM IFD allo-HSCT (MDS) (invasive aspergillosis, IA) , IFD 10 d (ATG) HSCT HSCT)。

GM [18-20] G : (1) : IA , IA GM/G IFD (200 mg/ ,3 /d)、 (200 ~ 400 mg/d)、



(200 mg/ ,2 /d)、 (4 mg• kg⁻¹• IFD)。

⁻¹,2 /d);(2) allo-HSCT : ,

(200 mg/ ,3 /d)、 (50 mg/d)、 IFD ,

(200~400 mg/d)、 (200 mg/ , IFD

2 /d)、 (4 mg• kg⁻¹• ⁻¹,2 /d (<7 d), ,

) (50 mg/d) 。 IFD ,

() (secondary anti-fungal prophylaxis) [27]。

IFD , IFD , 、 、 、 、 、

HSCT , B 。

IFD , IFD ()

, IFD IFD ,

HSCT ,IFD 8.8% ,

IFD IFD 5.7% ,IFD IFD /

14.6% ,

IFD IFD IFD

、 、 、 [24] 。

() ()

IFD , 1. : (1 800

(mg/d , 400 mg/d)、 (1

>0.5 × 10⁹/L) ,HSCT 70 mg/d , 50 mg/d)

3 , GVHD (100~150 mg/d) ; B

GVHD , ;

[4] 。

、 、 、 、 、

() B 。

4~7 d 、 、 、 、 、

IFD , , B。

[25-26] ; , B。

GM/G IFD , B、 。

IFD , B

(200 mg/ ,1 /12 h, 2 d, 200 mg/d 2 。

)、 (70 mg/d , 50 mg/d 2. : 、 、 、

)、 B(3 mg• kg⁻¹• d⁻¹)、 400 mg/d 。

B(0.5~1.5 mg• kg⁻¹• d⁻¹)、 (100~

150 mg/d) (1 6 mg• kg⁻¹• ⁻¹ ,

1 /12 h ; 4 mg• kg⁻¹• ⁻¹,1 /12 h ,

, 200 mg/ ,2 /d)。

,IFD ,

, (HSCT 。

) B。 3. :

() B 。

、 、 、 、 、

, IFD ,

(IFD)

(GM/G) , 4 。



Clin Infect Dis, 2014, 59(12):1696-1702. DOI: 10.1093/cid/ciu673.

[20] Petraitiene R, Petraitis V, Bacher JD, et al. Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1→3)-β-D-glucan in experimental invasive pulmonary aspergillosis [J]. Med Mycol, 2015, 53(6):558-568. DOI: 10.1093/mmy/myv034.

[21] Sulahian A, Porcher R, Bergeron A, et al. Use and limits of (1-3)-β-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis [J]. J Clin Microbiol, 2014, 52(7):2328-2333. DOI:10.1128/JCM.03567-13.

[22] Morrissey CO, Chen SC, Sorrell TC, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients; a randomised controlled trial [J]. Lancet Infect Dis, 2013, 13(6):519-528. DOI: 10.1016/S1473-3099(13)70076-8.

[23] Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? [J]. Br J Haematol, 2011, 153(6):681-697. DOI: 10.1111/j.1365-2141.2011.08650.x.

[24] Liu Q, Lin R, Sun J, et al. Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis [J]. Biol Blood Marrow Transplant, 2014, 20(8):1198-1203. DOI: 10.1016/j.bbmt.2014.04.016.

[25] Maschmeyer G, Heinz WJ, Hertenstein B, et al. Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study [J]. Eur J Clin Microbiol Infect Dis, 2013, 32(5):679-689. DOI: 10.1007/s10096-012-1794-4.

[26] Malhotra P, Makkar A, Guru Murthy GS, et al. Empirical amphotericin B therapy on day 4 or day 8 of febrile neutropenia [J]. Mycoses, 2014, 57(2):110-115. DOI: 10.1111/myc.12108.

[27] Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients; a randomized, controlled trial [J]. Clin Infect Dis, 2009, 48(8):1042-1051. DOI: 10.1086/597395.

[28] Garbati MA, Alasmari FA, Al-Tannir MA, et al. The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review [J]. Int J Infect Dis, 2012, 16(2):e76-81. DOI: 10.1016/j.ijid.2011.10.004.

[29] Candoni A, Caira M, Cesaro S, et al. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study [J]. Mycoses, 2014, 57(6):342-350. DOI: 10.1111/myc.12161.

[30] Price TH, Boeckh M, Harrison RW, et al. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection [J]. Blood, 2015, 126(18):2153-2161. DOI: 10.1182/blood-2015-05-645986.

[31] Wan L, Zhang Y, Lai Y, et al. Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV trial [J]. J Clin Oncol, 2015, 33(34):3999-4006. DOI: 10.1200/JCO.2014.60.5121.

[32] Caillet D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia [J]. J Clin Oncol, 2001, 19(1):253-259. DOI: 10.1200/JCO.2001.19.1.253.


[33] Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria [J]. Clin Infect Dis, 2008, 47(5):674-683. DOI: 10.1086/590566.

(:2017-03-27)
(:)

The Royal Society of Medicine

【网址】<https://www.rsm.ac.uk/>

【类型】



(The Royal Society of Medicine, RSM) 1805

,RSM
Medal
The Edward Jenner Medal
;RSM

400 , 60

(中国医科大学医学信息学院 范馨月 黄亚明)